Cryptococcus gattii infections: Contemporary aspects of epidemiology, clinical manifestations and management of infection

Future Microbiology

Volumn 8, Issue 12, 2013, Pages 1613-1631

  McMullan, Brendan Joseph ^a,b,c   Sorrell, Tania Christine ^d,e   Chen, Sharon Chih Ann ^d,e  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c University of Sydney   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

antifungal drugs; brain and lung cryptococcomas; Cryptococcus gattii; epidemiology; immune reconstitution syndrome; raised intracranial pressure

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; FUNGAL DNA; INTERNAL TRANSCRIBED SPACER; ITRACONAZOLE; POSACONAZOLE; RIBOSOME DNA; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANIMAL DISEASE; ANTIBIOTIC THERAPY; ANTIFUNGAL SUSCEPTIBILITY; ANTIGEN ANTIBODY REACTION; ASIA; BRAIN INFECTION; CEREBROSPINAL FLUID SHUNTING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DNA SEQUENCE; DRUG SUBSTITUTION; ECOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; ERADICATION THERAPY; EUCALYPTUS CAMALDULENSIS; EUROPE; FUNGUS CULTURE; GENE LOCUS; GENE PRODUCT; GENOTYPE; HIGH RISK POPULATION; HISTOPATHOLOGY; HISTORY OF MEDICINE; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCEPHALUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; INCUBATION TIME; INTRACRANIAL PRESSURE; KARYOTYPING; LUNG INFECTION; MAMMAL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MENINGITIS; MENINGOENCEPHALITIS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE HYDROCEPHALUS; PACIFIC ISLANDS; PNEUMONIA; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; RANDOM AMPLIFIED POLYMORPHIC DNA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION MAPPING; REVIEW; SEROTYPE; SIBLING; SOUTH AMERICA; TAXONOMY; THORAX RADIOGRAPHY; TREATMENT DURATION;

CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; HUMANS;

EID: 84889598037     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.123     Document Type: Review

References (121)

1. Park BJ, Wanneumuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among patients living with HIV/AIDS. AIDS 23, 525-530 (2009).
2. Kurtzman C, Fell JW, Boekhout T. The Yeasts: A Taxonomic Study (5th Edition). Elsevier Science, London, UK (2011).
3. Perfect JR, Casadevall A. The history of Cryptococcus and Cryptococcosis. In: Cryptococcus: From Human Pathogen to Model Yeast. Heitman J, Kozel TR, Kwon-Chung J, Perfect J, Casadevall A (Eds). American Society for Microbiology Press, Washington, DC, USA, 17-26 (2011).
4. Kwong-Chung K, Boekhout T, Fell JW, Diaz M. Proposal to conserve the name gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 51, 804-806 (2002). (Pubitemid 36251457)
5. MacDougall L, Kidd SE, Galanis E et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg. Infect. Dis. 13, 42-50 (2007). (Pubitemid 46057836)
6. CDC. Emergence of Cryptococcus gattii - Pacific Northwest, 2004-2010. Morb. Mortal. Wkly Rep. 59, 865-868 (2010).
7. Harris J, Lockhart S, Debess E et al. Cryptococcus gattii in the United States: Clinical aspects of infection with an emerging pathogen. Clin. Infect. Dis. 53, 1188-1195 (2011).
8. Hagen F, Colom MF, Swinne D et al. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg. Infect. Dis. 18, 1618-1624 (2012).
9. Chen SC-A, Slavin MA, Heath CH et al.; Australia and New Zealand Mycoses Interest Group (ANZMIG)-Cryptococcus Study. Clinical manifestations of Cryptococcus gattii infection: Determinants of neurological sequelae and death. Clin. Infect. Dis. 55, 789-790 (2012).
10. Sanfelice F. Contributo alla morfologia e biolgia dei blastomiceti che si sviluppano nei succhi di alcuni frutti. Ann. d' igiene 4, 463-495 (1894).
11. Gatti F, Eeckels R. An atypical strain of Cryptococcus neoformans (San Felice) Vuillemin, 1894. I. Description of the disease and of the strain. Ann. Soc. Belges Med. Trop. Parasitol. Mycol. 50, 689-693 (1970).
12. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am. J. Epidemiol. 120, 123-130 (1984). (Pubitemid 14076734)
13. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 128, 1642-1644 (1990). (Pubitemid 20212901)
14. Mitchell DH, Sorrell TC, Allworth AM et al. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome. Clin. Infect. Dis. 20, 611-616 (1995).
15. Seaton RA, Verma N, Naraqi S, Wembri JP, Warrell DA. Visual loss in immunocompetent patients with Cryptococcus neoformans var. gattii meningitis. Trans. R. Soc. Trop. Med. Hyg. 91, 44-49 (1997). (Pubitemid 27095499)
16. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin. Infect. Dis. 21, 28-34 (1995).
17. Chen S, Sorrell T, Nimmo G et al. Epidemiology and host-And variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin. Infect. Dis. 31, 499-508 (2000). (Pubitemid 32289583)
18. Laurenson IF, Trevett AJ, Lalloo DG et al. Meningitis caused by Cryptococcus neoformans var. gattii and var. neoformans in Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 90, 57-60 (1996). (Pubitemid 26069448)
19. Harris J, Lockhart S, Chiller T. Cryptococcus gattii: Where do we go from here? Med. Mycol. 50, 113-129 (2012).
20. Cogliati M. Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An atlas of the molecular types. Scientifica 2013, 675213 (2013).
21. Kidd SE, Hagen F, Tscharke RL et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl Acad. Sci. USA 101, 17258-17263 (2004). (Pubitemid 39627807)
22. Kidd SE, Chow Y, Mak S et al. Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columba, Canada, and the Pacific Northwest of the United States. Appl. Environ. Microbiol. 73, 1433-1443 (2007). (Pubitemid 46417866)
23. Kidd SE, Bach PJ, Hingston AO et al. Cryptococcus gattii dispersal mechanisms. British Columbia, Canada. Emerg. Infect. Dis. 13, 51-57 (2007). (Pubitemid 46057837)
24. Kwon-Chung KC, Varma A. Do major species concepts support one, or more species within Cryptococcus neoformans? FEMS Yeast Res. 6, 574-587 (2006). (Pubitemid 43725741)
25. Feng X, Fu X, Ling B, Wang L, Liao W, Yao Z. Development of a singleplex PCR assay for rapid identification and differentiation of Cryptococcus neoformans var. grubii, Cryptococcus neoformans var. neoformans, Cryptococcus gattii and hybrids. J. Clin. Microbiol. 51(6), 1920-1923 (2013).
26. D'Souza CA, Kronstad JW, Taylor G et al. Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. MBio 2, e00342-10 (2011).
27. Ngamskulrungroj P, Gilgado F, Faganello J et al. Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. PLoS ONE 4, e5862 (2009).
28. Bovers M, Diaz MR, Hagen F et al. Identification of genotypically diverse Cryptococcus neoformans and Cryptococcus gattii isolates by Luminex xMAP technology. J. Clin. Microbiol. 45, 1874-1883 (2007). (Pubitemid 46933920)
29. Meyer W, Aanensen DM, Boekhout T et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med. Mycol. 47, 561-570 (2009).
30. Sidrim JJ, Costa AK, Costa F et al. Molecular methods for the diagnosis and characterization of Cryptococcus: A review. Can. J. Microbiol. 56, 445-458 (2010).
31. Meyer W, Gilgado F, Ngamskulrungroj P et al. Molecular typing of the Cryptococcus neoformans/Cryptococcus gattii species complex. In: Cryptococcus: From Human Pathogen to Model Yeast. Heitman J, Kozel TR, Kwon-Chung J, Perfect J, Casadevall A (Eds). American Society for Microbiology, Press, Washington, DC, USA, 327-357 (2011).
32. Hoang LM, Phillips P, Galanis E. Cryptococcus gattii: A review of the epidemiology, clinical presentation, diagnosis, and management of this endemic yeast in the Pacific Northwest. Clin. Microbiol. Newsl. 33, 187-195 (2011).
33. Byrnes EJ, Li W, Lewit Y et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 6, e1000850 (2010).
34. Iqbal N, Debess EE, Wohrle R et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J. Clin. Microbiol. 48, 539-544 (2010).
35. Campbell LT, Fraser JA, Nichols CB, Dietrich FS, Carter D, Heitman J. Clinical and environmental isolates of Cryptococcus gattii from Australia that retain sexual fecundity. Euk. Cell 4, 1410-1419 (2005). (Pubitemid 41176695)
36. Chen SC, Currie BJ, Campbell HM et al. Cryptococcus neoformans var. gattii in northern Australia: Existence of an environmental source other than known host eucalypts. Trans. R. Soc. Trop. Med. Hyg. 91, 547-550 (1997). (Pubitemid 27478643)
37. Laman M, Hwaihwanje I, Davis TM, Manning L. Cryptococcal meningitis in immunocompetent Papua New Guinean children. Trop. Doct. 40, 61-63 (2010).
38. Chaturvedi V, Chaturvedi S. Cryptococcus gattii: A resurgent fungal pathogen. Trends Microbiol. 19, 564-571 (2011).
39. Stephen C, Lester S, Black W, Fyfe M, Raverty S. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can. Vet. J. 43, 792-794 (2002). (Pubitemid 35314748)
40. Bartlett K, Fyfe MW, MacDougall LA. Environmental Cryptococcus neoformans var. gattii in British Columbia, Canada. Am. J. Resp. Crit. Care Med. 167, A499 (2003).
41. Galanis E, MacDougall L. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg. Infect. Dis. 16, 251-257 (2010).
42. Climate Impacts Group. The Washington Climate Change Impacts Assessment. McGuire Elsner M, Littell J, Whitely Binders L (Eds). Center for Science in the Earth System, Joint Institute for the Study of the Atmosphere and Oceans, University of Washington, WA, USA (2009).
43. Fraser JA, Giles SS, Wenink EC et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437, 1360-1364 (2005). (Pubitemid 41568682)
44. Carriconde F, Gilgado F, Arthur I et al. Clonality and a-A recombination in the Australian Cryptococcus gattii VGII population - An emerging outbreak in Australia. PLoS ONE 6, e16936 (2011).
45. Escandon P, Sanchez A, Martinez M, Meyer W, Castaneda E. Molecular epidemiology of clinical and environmental isolates of the Cryptococcus neoformans species complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia. FEMS Yeast Res. 6, 625-635 (2006). (Pubitemid 43725747)
46. Colom MF, Hagen F, Gonzalez A et al. Ceratonia siliqua (carob) trees as natural habitat and source of infection by Cryptococcus gattii in the Mediterranean environment. Med. Mycol. 50, 67-73 (2012).
47. Sukroongreung S, Nilakul C, Ruangsomboon O, Chuakul W, Eampokalap B. Serotypes of Cryptococcus neoformans isolated from patients prior to and during the AIDS era in Thailand. Mycopathologia 135, 75-78 (1976).
48. Chowdhary A, Rhandhawa HS, Prakash A, Meis JF. Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: An update. Crit. Rev. Microbiol. 38, 1-16 (2012).
49. Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan Africa. J. Infect. Dis. 192, 888-892 (2005). (Pubitemid 41193087)
50. Lemmer K, Naumann D, Raddatz B, Tintelnot K. Molecular typing of Cryptococcus neoformans by PCR fingerprinting, in comparison with serotyping and Fourier transform infrared-spectroscopy-based phenotyping. Med. Mycol. 42, 135-147 (2004). (Pubitemid 38489023)
51. Bogaerts J, Rouvroy D, Taelman H et al. AIDS-Associated cryptococcal meningitis in Rwanda (1983-1992): Epidemiologic and diagnostic features. J. Infect. 39, 32-37 (1999). (Pubitemid 29396603)
52. Morgan J, McCarthy KM, Gould S et al. Cryptococcus gattii infection: Characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin. Infect. Dis. 43, 1077-1080 (2006). (Pubitemid 44631112)
53. Howell SA. Hazen KC. Candida, Cryptococcus, and other yeasts of medical importance. In: Manual of Clinical Microbiology (10th Edition). Versalovic J, Carroll KC, Guido F, Jorgensen JH, Landry ML, Warnock DW (Eds). American Society for Microbiology Press, Washington, DC, USA, 1793-1821 (2011).
54. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg. Infect. Dis. 17, 193-199 (2011).
55. Marr KA, Datta K, Pirofski L, Barnes R. Cryptococcus gattii infection in healthy hosts: A sentinel for subclinical immunodeficiency. Clin. Infect. Dis. 54, 153 (2012).
56. Steele KT, Thakur R, Nthobatsang R, Steenhoff AP, Bisson GP. In hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Med. Mycol. 48, 1112-1115 (2010).
57. Wozniak K, Levitz S. T cell and dendritic cell immune responses to Cryptococcus. In: Cryptococcus: From Human Pathogen to Model Yeast. Heitman J, Kozel TR, Kwon-Chung J, Perfect J, Casadevall A (Eds), American Society for Microbiology Press, Washington, DC, USA, 387-396 (2011).
58. Dromer F, Mathoulin-Pe ́lissier S, Launay O, Lortholary O; French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: The CryptoA/D study. PLoS Med. 4, e21 (2007).
59. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291-322 (2010).
60. Speed B, Kaldor J. Rarity of cryptococcal infection in children. Paed. Infect. Dis. J. 16, 536-537 (1997).
61. Meiring ST, Quan VC, Cohen C et al.; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005-2007. AIDS 26, 2307-2314 (2012).
62. Severo CB, Xavier MO, Gazzoni AF, Severo LC. Cryptococcosis in children. Ped. Resp. Rev. 10, 166-171 (2009).
63. Seaton RA, Hamilton AJ, Hay RJ, Warrell DA. Exposure to Cryptococcus neoformans var. gattii - A seroepidemiological study. Trans. R. Soc. Trop. Med. Hyg. 90, 508-512 (1996). (Pubitemid 26356626)
64. Goldman DL, Khine H, Abadi J et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107, e66 (2001).
65. Corrêa Mdo P, Oliveira EC, Duarte RR, Pardal PP, Oliveira Fde M, Severo LC. Cryptococcosis in children in the state of Para ́, Brazil. Rev. Soc. Bras. Med. Trop. 32, 505-508 (1999).
66. Krockenberger MB, Canfield PJ, Malik R. Cryptococcus neoformans var. gattii in the koala (Phascolarctos cinereus): A review of 43 cases of cryptococcosis. Med. Mycol. 41, 225-234 (2003). (Pubitemid 37059200)
67. O'Brien CR, Krockenberger MB, Wigney DI, Martin P, Malik R. Retrospective study of feline and canine cryptococcosis in Australia from 1981 to 195 cases. Med. Mycol. 42, 449-460 (2004). (Pubitemid 39445477)
68. Miller WG, Padhye AA, van Bonn W, Jensen E, Brandt ME, Ridgway SH. Cryptococcosis in a bottlenose dolphin (Tursiops truncatus) caused by Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 40, 721-724 (2002). (Pubitemid 34130917)
69. Norman S, Raverty S, Zabek EJ et al. Maternal-fetal transmission of Cryptococcus gattii in harbor porpoise. Emerg. Infect. Dis. 17, 304-305 (2011).
70. Galanis E, Hoang L, Kibsey P, Morshed M, Philips P. Clinical presentation, diagnosis and management of Cryptococcus gattii cases: Lessons learned from British Columbia. Can. J. Infect. Dis. Med. Microbiol. 20, 23-25 (2009).
71. Mistry N, Tan K, Shokravi M, Hoang L. Cryptococcus gattii infections with cutaneous involvement. J. Cutan. Med. Surg. 15, 236-237 (2011).
72. Araujo BS, Bay M, Reichert R, Goldani LZ. Intra-Abdominal cryptococcosis by Cryptococcus gattii: Case report and review. Mycopathologia 174, 81-85 (2012).
73. MacDougall L, Fyfe M. Emergence of Cryptococcus gattii in a novel environment provides clues to its incubation period. J. Clin. Microbiol. 44, 1851-1852 (2006). (Pubitemid 43726282)
74. Lindberg J, Hagen F, Laursen A, Stenderup J, Boekhout T. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg. Infect. Dis. 13, 178-179 (2007). (Pubitemid 46057867)
75. Georgi A, Schneemann M, Tintelnot K et al. Cryptococcus gattii meningoencephalitis in an immunocompetent person 13 months after exposure. Infection 37, 370-373 (2009).
76. Hagen F, van Assen S, Luijckx G et al. Activated dormant Cryptococcus gattii infection in a Dutch tourist who visited Vancouver island (Canada): A molecular epidemiological approach. Med. Mycol. 48, 528-531 (2010).
77. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37, 3204-3209 (1999). (Pubitemid 29455206)
78. Dromer F, Casadevall A, Perfect J, Sorrell T. Cryptococcus neoformans: Latency and disease. In: Cryptococcus: From Pathogen to Model Yeast. Heitman J, Kozel TR, Kwon-Chung J, Perfect J, Casadevall A (Eds). American Society for Microbiology Press, Washington, DC, USA, 431 (2011).
79. Lalloo D, Fisher D, Naraqi N et al. Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously health Melanesian adults in Papua New Guinea. Q. J. Med. 87, 343-349 (1994).
80. Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin. Infect. Dis. 14, 1142-1144 (1992).
81. Yang CJ, Hwang JJ, Wang TH et al. Clinical and radiographic presentations of pulmonary cryptococcosis in immunocompetent patients. Scand. J. Infect. Dis. 38, 788-793 (2006).
82. Graybill JR, Sobel J, Saag M et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin. Infect. Dis. 30, 47-54 (2000). (Pubitemid 30067061)
83. Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin. Infect. Dis. 28, 629-633 (1999). (Pubitemid 29242545)
84. Chen SC, Korman TK, Slavin MA et al. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin. Infect. Dis. 57(4), 543-551 (2013).
85. Phillips P, Chapman K, Sharp M et al. Dexamethasone in Cryptococcus gattii central nervous system infection. Clin. Infect. Dis. 49, 591-595 (2009).
86. Lane M, McBride J, Archer J. Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis. Neurology 63, 713-714 (2004). (Pubitemid 39100832)
87. Einsiedel L, Gordon DL, Dyer Jr. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin. Infect. Dis. 9, e78-e82 (2004).
88. Boulware DR, Bonham SC, Meya DB et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J. Infect. Dis. 202, 962-970 (2010).
89. Wiesner DL, Boulware DR. Cryptococcus-related immune reconstitution inflammatory syndrome (IRIS): Pathogenesis and its clinical implications. Curr. Fungal Infect. Rep. 5, 252-261 (2011).
90. Jenny A, Pandithage K, Fisher DA, Currie BJ. Cryptococcus infection in tropical Australia. J. Clin. Microbiol. 42, 3865-3868 (2004). (Pubitemid 39045733)
91. Baddley JW, Perfect JR, Oster RA et al. Pulmonary cryptococcosis in patients without HIV infection: Factors associated with disseminated disease. Eur. J. Clin. Microbiol. Infect. Dis. 27, 937-943 (2008).
92. Charlier C, Dromer F, Leveque C et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS ONE 3, e1950 (2008).
93. Smith AB, Smirniotopoulos JG, Rushing EJ. Central nervous system infections associated with human immunodeficiency virus infection: Radiologic-pathologic correlation. Radiographics 28, 2033-2058 (2008).
94. Diaz MR, Nguyen MH. Diagnostic approach based on capsular antigen, capsule detection, b-glucan and DNA analysis. In: Cryptococcus: From Human Pathogen to Model Yeast. Heitman J, Kozel TR, Kwon-Chung J, Perfect J, Casadevall A (Eds). American Society for Microbiology Press, Washington DC, USA, 547-564 (2011).
95. Saha DC, Xess I, Jain N. Evaluation of conventional and serological methods for rapid diagnosis of cryptococcosis. Indian J. Med. Res. 127, 483-488 (2008).
96. Petter R, Kang BS, Boekhout T, Davis BJ, Kwon-Chung KJ. A survey of heterobasidiomycetous yeasts for the presence of the genes homologous to virulence factors of Filobasidiella neoformans, CNLAC1 and CAP59. Microbiology 147, 2029-2036 (2001). (Pubitemid 32785484)
97. Okoli I, Oyeka CA, Kwon-Chung KJ et al. Cryptotrichosporon anacardii gen nov, sp nov, a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. FEMS Yeast Res. 7, 339-350 (2007).
98. Hansen J, Sletcha ES, Marcellene A et al. Large-scale evaluation of the Immuno-Mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin. Vaccine Immunol. 20, 52-55 (2013).
99. Lindsley M, Mekha N, Baggett HC et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin. Infect. Dis. 53, 321-325 (2011).
100. Jarvis JN, Percival A, Bauman S et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-Associated cryptococcal meningitis. Clin. Infect. Dis. 53, 1019-1023 (2011).
101. McMullan B, Halliday C, Sorrell T et al. Evaluation of the cryptococcal antigen (CrAg) lateral flow assay in a diagnostic mycology laboratory. PLoS ONE 7, e49541 (2012).
102. Katsu M, Kidd S, Ando A et al. The internal transcribed spacers and 5.8S rRNA gene show extensive diversity among isolates of the Cryptococcus neoformans species complex. FEMS Yeast Res. 4, 377-388 (2004). (Pubitemid 38156202)
103. Kaocharoen S, Wang B, Tsui KM, Trilles L, Kong F, Meyer W. Hyperbranched rolling circle amplification as a rapid and sensitive method for species identification within the Cryptococcus species complex. Electrophoresis 29, 3183-3191 (2008).
104. Pinto A, Halliday C, Zahra M et al. Matrix-Assisted laser desorption ionization-Time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS ONE 6, e25712 (2011).
105. McTaggart L, Lei E, Richardson SE et al. Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix assisted laser desorption ionization-Time-of-flight mass spectrometry (MALDI-TOF MS). J. Clin. Microbiol. 49, 3050-3053 (2011).
106. Firacative C, Trilles L, Meyer W. MALDI TOF MS enables the rapid identification of the major molecular types within the Cryptococcus neoformans/C. gattii species complex. PLoS ONE 7, e37566 (2012).
107. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M et al. Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-Type susceptibility endpoint distributions and epidemiological cut-off values for amphotericin B and flucytosine. Antimicrob. Agents Chemother. 56, 3107-3113 (2012).
108. Espinel-Ingroff A, Aller AI, Canton E et al. Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-Type susceptibility endpoint distributions and epidemiological cut-off values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob. Agents Chemother. 56, 5898-5906 (2012).
109. Ellis D, Sorrell T, Chen S. Impact of antifungal resistance in Australia. Microbiol. Aust. 28, 171-173 (2007).
110. Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53, 309-311 (2009).
111. Matos CS, de Souza Andrade A, Oliveira NS, Barros TF. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: Molecular types and antifungal susceptibilities. Eur. J. Clin. Microbiol. Infect. Dis. 31, 1647-1652 (2012).
112. Chen YC, Chang SC, Shih CC et al. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn. Microbiol. Infect. Dis. 36, 175-183 (2000).
113. Torres-Rodri ́guez JM, Alvarado-Rami ́rez E, Murciano F, Sellart M. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococus gattii. J. Antimicrob. Chemother. 62, 205-206 (2008). (Pubitemid 351865898)
114. Trilles L, Meyer W, Wanke B, Guarro J, Lazera M. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med. Mycol. 50, 328-332 (2012).
115. Hagen F, Illnait-Zaragozi M-T, Bartlett KH et al. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob. Agents Chemother. 54, 5139-5145 (2010).
116. Lockhart SR, Iqbal N, Bolden CB et al.; Cryptococcus gattii PNW Public Health Working Group. Epidemiologic cut-off values for triazole drugs in Cryptococcus gattii: Correlation of molecular type and in vitro susceptibility. Diagn. Microbiol. Infect. Dis. 73, 144-148 (2012).
117. Fisher D, Lo D, Burrow J, Currie B. Cryptococcus neoformans in tropical northern Australia: Predominantly variant gattii with good outcomes. Aust. NZ J. Med. 23, 678-681 (1993).
118. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O; French Cryptococcosis Study Group. Major role for amphotericin B-f lucytosine combination in severe cryptococcosis. PLoS ONE 3, e2870 (2008).
119. Chau TT, Mai NH, Phu NH et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var. grubii in the absence of underlying disease. BMC Infect. Dis. 10, 199 (2010).
120. Rajasingham R. Meva DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J. Acq. Immunodef. Syndr. 59, e85-e91 (2012).
121. Martins LM, de Andrade HM, Vainstein MH et al. Immunoproteomics and immunoinformatics analysis of Cryptococcus gattii: Novel candidate antigens for diagnosis. Future Microbiol. 8, 549-563 (2013).